FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

FDA Wants Generic Drugs Harmonized Globally

FDA commissioner Scott Gottlieb says the agency is seeking international harmonization of generic drug scientific and technical requirements as a way ...

Human Drugs

Groups Praise FDA Expansion Cohorts Guidance

Five stakeholders respond to an FDA draft guidance on use of expansion cohorts in some oncology trials.

Medical Devices

FDA Cybersecurity MOU with Homeland Security Department

FDA and the Department of Homeland Security sign a Memorandum of Understanding on medical device cybersecurity coordination.

Human Drugs

FDA Looking at Mitochondrial Drugs and Cancer Cells: Spotlight

A CDER Spotlight on Science describes how the Office of Pharmaceutical Quality is researching the effects of mitochondrial drugs on cancer cells.

Federal Register

FDA Posts Lists of Molecular Targets for Pediatric Cancer

Federal Register notice: FDAs Oncology Center of Excellence Pediatric Oncology Program has announced the creation of two lists of molecular targets fo...

Marketing

Eisai Sales Rep Made False, Misleading Statements: OPDP

CDERs Office of Prescription Drug Promotion cautions Eisai about a sales representatives misleading presentation on the safety of its Fycompa.

Federal Register

Class 2 for Herpes Virus Lesion Panel IVD

Federal Register notice: FDA classifies the herpes virus nucleic acid-based cutaneous and mucocutaneous lesion panel into Class 2 (special controls).

Federal Register

Regulatory Review Period Determined for Tremfya

Federal Register notice: FDA determines the patent extension-related regulatory review period for Janssen Biotechs Tremfya (guselkumab), indicated for...

Federal Register

Gil Debarred for 6 Years Over Healthcare Fraud

Federal Register notice: FDA debars Isachi Gil for six years from providing services in any capacity to a person that has an approved or pending drug ...

Marketing

FDA Proposes 2 Drug Communication Studies

FDA solicits comments on two proposed CDER Office of Prescription Drug Promotion research projects.